| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM199204233261705 |
| P698 | PubMed publication ID | 1552913 |
| P2093 | author name string | P. I. Schmitz | |
| van der Meché FG | |||
| F. G. van der Meché | |||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Guillain–Barré syndrome | Q205214 |
| randomized experiment | Q1231081 | ||
| P304 | page(s) | 1123-1129 | |
| P577 | publication date | 1992-04-01 | |
| 1992-04-23 | |||
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group | |
| P2283 | uses | randomized experiment | Q1231081 |
| P478 | volume | 326 |
| Q89702465 | A Comparative Study of IVIG versus IVIG with IV Methylprednisolone in Guillain-Barre Syndrome |
| Q37618626 | A Rare case of Guillain-Barré syndrome in pregnancy treated with plasma exchange |
| Q58551488 | A Rare case of recurrent Guillain-Barré syndrome without albuminocytological dissociation |
| Q40208214 | A clinical prognostic scoring system for Guillain-Barré syndrome |
| Q36455004 | A comparison between plasmapheresis and intravenous immunoglobulin in children with Guillain-Barré syndrome in Upper Egypt |
| Q89777975 | A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b |
| Q36316836 | A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group |
| Q40240147 | A rare case of infectious mononucleosis complicated by guillain-barre syndrome |
| Q37700839 | A young patient with multisystem complications after cytomegalovirus infection |
| Q74452605 | AAEM case report 4: Guillain-Barré syndrome. American Association of Electrodiagnostic Medicine |
| Q74587591 | Ability to remove immunoglobulins and anti-ganglioside antibodies by plasma exchange, double-filtration plasmapheresis and immunoadsorption |
| Q73684939 | Abstracts of the 13th Meeting of the European Neurological Society. 14-18 June 2003, Istanbul, Turkey |
| Q33590947 | Acute neuromuscular respiratory paralysis |
| Q41535347 | Acute peripheral neuropathy in adults. Guillain-Barré syndrome and related disorders |
| Q34929493 | Advances in the management of Guillain-Barré syndrome. |
| Q73223310 | Adverse effect of polyvalent immunoglobulin in the treatment of Guillain-Barre syndrome |
| Q40790004 | Adverse effects of intravenous immunoglobulin |
| Q33733019 | Adverse effects of intravenous immunoglobulin therapy |
| Q34687015 | An immunocompetent adult patient with hepatitis and guillain-barré syndrome after cytomegalovirus infection |
| Q73539311 | Anti-PMP22 antibodies in patients with inflammatory neuropathy |
| Q42277583 | Anti‐GM1 IgG antibodies and campylobacter bacteria in Guillain‐Barré syndrome: Evidence of molecular mimicry |
| Q47933107 | Anti–GM1 IgG antibodies induce leukocyte effector functions via Fcγ receptors |
| Q41560838 | Approach to generalized weakness and peripheral neuromuscular disease |
| Q41114249 | Appropriate therapeutic use of immunoglobulin |
| Q28261039 | Autoimmune neuromuscular disorders |
| Q41293519 | Autoimmune responses in peripheral nerve |
| Q28301911 | Axonal Guillain-Barré syndrome: concepts and controversies |
| Q36602762 | Basic principles of intravenous immunoglobulin (IVIg) treatment |
| Q44169961 | Behavioral, climatic, and environmental risk factors for Zika and Chikungunya virus infections in Rio de Janeiro, Brazil, 2015-16. |
| Q48203694 | Campylobacter jejuni gastroenteritis and acute encephalopathy |
| Q40512379 | Campylobacter jejuni infection and the Guillain-Barre syndrome: mechanisms and implications |
| Q41717750 | Campylobacter jejuni infection as a cause of the Guillain-Barré syndrome |
| Q33975353 | Campylobacter species and Guillain-Barré syndrome |
| Q37680036 | Changes in the severity and subtype of Guillain-Barré syndrome admitted to a specialist Neuromedical ICU over a 25 year period. |
| Q77157595 | Chronic inflammatory demyelinating polyradiculoneuropathy: superiority of protein A immunoadsorption over plasma exchange treatment |
| Q41663344 | Clinical and neurophysiological assessment of immunoglobulin therapy in five patients with multifocal motor neuropathy |
| Q37626126 | Clinical applications of intravenous immunoglobulins in neurology |
| Q30451700 | Clinical applications of therapeutic apheresis |
| Q35765164 | Clinical characteristics of childhood guillain-barré syndrome |
| Q35121624 | Clinical features and prognosis with Guillain-Barré syndrome |
| Q28296591 | Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome |
| Q35467350 | Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies |
| Q71832892 | Combined high-dose 7S-IgG and dexamethasone is effective in severe polyneuropathy of the POEMS syndrome |
| Q36070382 | Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study |
| Q39632316 | Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases |
| Q33901517 | Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome |
| Q33572099 | Criteria for the appropriate drug utilisation of immunoglobulin |
| Q74775379 | Cross-reactive anti-galactocerebroside antibodies and Mycoplasma pneumoniae infections in Guillain-Barré syndrome |
| Q73573153 | Current treatment in acute demyelinating polyneuropathy (Guillain-Barré syndrome) |
| Q80196495 | Cytomegalovirus disease with Guillain-Barré syndrome in a cadaver renal allograft recipient: cause or coincidence |
| Q41838846 | Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barre syndrome |
| Q43049261 | Dendritic cells from patients with rheumatoid arthritis lack the interleukin 13 mediated increase of Fc gamma RII expression, which has clear functional consequences |
| Q36119226 | Dendritic cells, Fc{gamma} receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis |
| Q55283357 | Dengue fever complicated with Guillain-Barré syndrome: a case report and review of the literature. |
| Q48909912 | Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria |
| Q35453309 | Diphtheritic polyneuropathy: a clinical study and comparison with Guillain-Barré syndrome |
| Q36700047 | Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues |
| Q45175335 | Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics |
| Q33590504 | Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration |
| Q56772109 | Early prediction of prognosis in Guillain–Barré syndrome |
| Q34686090 | Early recognition of poor prognosis in Guillain-Barre syndrome |
| Q44738594 | Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial |
| Q36484438 | Efficacy of Intravenous Immunoglobulin in Neurological Diseases. |
| Q73979986 | Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome |
| Q64261346 | Efficient design and analysis of randomized controlled trials in rare neurological diseases: An example in Guillain-Barré syndrome |
| Q42714677 | Electrodiagnostic criteria for polyneuropathy and demyelination: application in 135 patients with Guillain-Barré syndrome. Dutch Guillain-Barré Study Group |
| Q102058412 | Emergency Apheresis |
| Q22241376 | Emerging drugs for Guillain-Barré syndrome |
| Q36317618 | Epidemiological study of Guillain-Barré syndrome in south east England |
| Q41475129 | Evaluation and treatment of respiratory failure in neuromuscular disease |
| Q24630092 | Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology |
| Q64926451 | Excellent Response to Plasma Exchange in Three Patients With Enterovirus-71 Neurological Disease. |
| Q73418747 | Failure of intravenous immunoglobulin (IVIg) therapy in experimental autoimmune neuritis (EAN) of the Lewis rat |
| Q55078770 | First Reported Case of Respiratory Syncytial Virus Infection Causing Guillain-Barré Syndrome. |
| Q41225078 | Gammagard and reported hepatitis C virus episodes |
| Q49483052 | Gamunex® in Guillain-Barré Syndrome: A Postmarketing, Retrospective, Observational Study |
| Q36070406 | Give or take? Intravenous immunoglobulin or plasma exchange for Guillain-Barré syndrome |
| Q33918862 | Guillain Barré syndrome. |
| Q41382143 | Guillain-Barre syndrome |
| Q73239553 | Guillain-Barré Syndrome |
| Q24276200 | Guillain-Barré syndrome |
| Q77326744 | Guillain-Barré syndrome |
| Q93891189 | Guillain-Barré syndrome |
| Q34117850 | Guillain-Barré syndrome (GBS). |
| Q71824503 | Guillain-Barré syndrome after an operation on the spine. A case report |
| Q34466388 | Guillain-Barré syndrome and postbariatric surgery polyneuropathies. |
| Q22252353 | Guillain-Barré syndrome and variants |
| Q40129424 | Guillain-Barré syndrome as first presentation of systemic lupus erythematosus: a rare manifestation complicated by IVIg-induced splenic infarct |
| Q43108880 | Guillain-Barré syndrome in a patient with chronic lymphocytic leukaemia |
| Q33180146 | Guillain-Barré syndrome in a patient with non-Hodgkin's lymphoma |
| Q31874413 | Guillain-Barré syndrome with IgM antibody to the ganglioside GalNAc-GD1a |
| Q40463616 | Guillain-Barré syndrome. Clinical manifestations and directions for treatment. |
| Q39011456 | Guillain-Barré syndrome: a century of progress |
| Q40371882 | Guillain-Barré syndrome: clinical and immunological aspects |
| Q35690159 | Guillain-Barré syndrome: epidemiology, pathophysiology and management |
| Q36962998 | Guillain-Barré syndrome: rehabilitation outcome and recent developments |
| Q72729308 | Guillain-Barré syndrome: the evolution of therapy |
| Q86574901 | Guillain-barré syndrome |
| Q22248108 | Guillain–Barré Syndrome |
| Q22251013 | Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis |
| Q34058083 | Guillian Barré syndrome--recent advances |
| Q38540049 | Headache and Pain in Guillain-Barré Syndrome |
| Q91908249 | Hepatitis E virus-associated Guillain-Barre syndrome: Revision of the literature |
| Q72377527 | High dose immunoglobulin therapy is effective in the Miller Fisher syndrome |
| Q71373790 | High dose intravenous immune globulins and plasma exchange in Guillain-Barré Syndrome |
| Q53854440 | High‐dose immunoglobulin therapy for Guillain−Barré syndrome in Japanese children |
| Q35918443 | Hospital Admissions, Transfers and Costs of Guillain-Barré Syndrome |
| Q41663659 | Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy |
| Q22252627 | IVIG treatment and prognosis in Guillain-Barré syndrome |
| Q49299297 | IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety |
| Q36164827 | IVIg in idiopathic autoimmune neuropathies: analysis in the light of the latest results. |
| Q60933975 | IVIg-induced plasmablasts in patients with Guillain-Barré syndrome |
| Q38842992 | Immune Gamma Globulin Therapeutic Indications in Immune Deficiency and Autoimmunity |
| Q71692937 | Immune globulin therapy in children with Guillain-Barré syndrome |
| Q53977216 | Immune globulins are effective in severe pediatric Guillain-Barré syndrome. |
| Q86421496 | Immunoglobulin G Fc N-glycosylation in Guillain-Barré syndrome treated with intravenous immunoglobulin |
| Q40494876 | Immunoglobulin treatment in epilepsy, a review of the literature |
| Q37602031 | Immunomodulatory therapies in neurologic critical care |
| Q36484418 | Immunotherapy in Peripheral Neuropathies |
| Q35172337 | Immunotherapy in autoimmune neuromuscular disorders |
| Q89311940 | Immunotherapy of Guillain-Barré syndrome |
| Q40457021 | Impairment, disability, or handicap in peripheral neuropathy: analysis of the use of outcome measures in clinical trials in patients with peripheral neuropathies |
| Q34720405 | Improved serological diagnosis stresses the major role of Campylobacter jejuni in triggering Guillain-Barré syndrome |
| Q41663188 | In vitro effects of polyvalent immunoglobulin for intravenous use. |
| Q42241131 | Increased circulating Th17 cell populations and elevated CSF osteopontin and IL-17 concentrations in patients with Guillain-Barré syndrome |
| Q71941667 | Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barré syndrome, myasthenia gravis and dermatomyositis |
| Q90403599 | Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome |
| Q58861264 | Indications et mécanismes d’action des immunoglobulines intraveineuses dans les pathologies auto-immunes et inflammatoires systémiques |
| Q33596409 | Indications for intravenous gammaglobulin therapy in inflammatory myopathies |
| Q83226673 | Inflammatory demyelinating neuropathies |
| Q37329516 | Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment update |
| Q40977398 | Inflammatory neuropathies--pathogenesis and the role of intravenous immune globulin |
| Q37052679 | Inpatient management of guillain-barré syndrome |
| Q72164946 | Intrathecal rubella antibodies in an adolescent with Guillain-Barré syndrome after mumps-measles-rubella vaccination |
| Q74137567 | Intravenous gammaglobulin treatment in chronic progressive multiple sclerosis |
| Q51132813 | Intravenous immune globulin in the Guillain-Barré syndrome. |
| Q35542385 | Intravenous immune globulins: an update for clinicians |
| Q82162309 | Intravenous immunoglobulin and Guillain-Barré syndrome |
| Q24193522 | Intravenous immunoglobulin for Guillain-Barré syndrome |
| Q24202100 | Intravenous immunoglobulin for Guillain-Barré syndrome |
| Q24234992 | Intravenous immunoglobulin for Guillain-Barré syndrome |
| Q24244575 | Intravenous immunoglobulin for Guillain-Barré syndrome |
| Q24247429 | Intravenous immunoglobulin for Guillain-Barré syndrome |
| Q35187840 | Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, double-blind trial |
| Q77157630 | Intravenous immunoglobulin for cranial polyneuropathy associated with Campylobacter jejuni infection |
| Q34574581 | Intravenous immunoglobulin in neurological disease: a specialist review. |
| Q38308436 | Intravenous immunoglobulin in neurology--mode of action and clinical efficacy |
| Q33497629 | Intravenous immunoglobulin in rheumatic disease |
| Q36359695 | Intravenous immunoglobulin in therapy of peripheral neuropathy |
| Q77398105 | Intravenous immunoglobulin inhibits IgE production in human B lymphocytes |
| Q36812703 | Intravenous immunoglobulin therapy for acquired coagulation inhibitors: a critical review |
| Q33369796 | Intravenous immunoglobulin therapy in antiphospholipid syndrome |
| Q36602799 | Intravenous immunoglobulin therapy in neurological diseases during pregnancy |
| Q36602775 | Intravenous immunoglobulin therapy in paraneoplastic neurological syndromes |
| Q73573158 | Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome |
| Q33735178 | Intravenous immunoglobulin treatment in neurological diseases |
| Q34124893 | Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion |
| Q40866049 | Intravenous immunoglobulin treatment of neurological autoimmune diseases |
| Q34431762 | Intravenous immunoglobulin vs plasma exchange in treatment of mechanically ventilated adults with Guillain-Barré syndrome |
| Q36602782 | Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis |
| Q91706132 | Introduction to therapeutic plasma exchange |
| Q33419638 | Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe |
| Q59413122 | La place des immunoglobulines intraveineuses en neurologie |
| Q58416373 | Les traitements du syndrome de Guillain-Barré de l'adulte: place des échanges plasmatiques |
| Q42551864 | Lethal hypersensitivity myocarditis associated with the use of intravenous gammaglobulin for Guillain-Barré syndrome, in combination with phenytoin |
| Q28368289 | Lipopolysaccharides from Campylobacter jejuni O:41 strains associated with Guillain-Barré syndrome exhibit mimicry of GM1 ganglioside |
| Q74577772 | Long-term impact on work and private life after Guillain-Barré syndrome |
| Q43660153 | Massive intravenous immunoglobulin treatment in pregnancy complicated by Guillain-Barré Syndrome |
| Q33660838 | Medications used in the treatment of multiple sclerosis. |
| Q47558569 | Miller-Fisher syndrome after coronary artery bypass surgery |
| Q35918784 | Modifying the Medical Research Council grading system through Rasch analyses |
| Q35753525 | Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases |
| Q34798030 | Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study |
| Q42155763 | Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS. |
| Q40649464 | Neuro-intensive care of the pregnant woman. |
| Q72176233 | Neurology |
| Q34047113 | Neuromuscular diseases associated with HIV-1 infection |
| Q41736714 | Neuromuscular disorders and acute respiratory failure |
| Q34990095 | Neuromuscular disorders in the intensive care unit |
| Q41173378 | New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins |
| Q34990105 | New therapies: plasmapheresis, intravenous immunoglobulin, and monoclonal antibodies |
| Q73608375 | Normal human plasma contains antibodies that specifically block neuropathy-associated human anti-GM1 IgG-antibodies |
| Q38601233 | Outcomes for patients with Guillain-Barré syndrome requiring mechanical ventilation: a literature review |
| Q35105056 | Paraneoplastic neurologic syndromes |
| Q41663237 | Passage of intravenous immunoglobulin and interaction with the CNS. |
| Q34409385 | Pathogenesis and treatment of immune-mediated neuropathies |
| Q35683333 | Pathogenicity of anti-ganglioside antibodies in the Guillain-Barré syndrome. |
| Q64131272 | Patología neuromuscular en cuidados intensivos |
| Q35149167 | Pediatric Guillain-Barré syndrome: Indicators for a severe course |
| Q35156933 | Peripheral neuropathies in clinical practice |
| Q80247543 | Peripheral neuropathy |
| Q37807823 | Plasma exchange and intravenous immunoglobulins: Mechanism of action in immune-mediated neuropathies |
| Q24202179 | Plasma exchange for Guillain-Barré syndrome |
| Q57689726 | Plasma exchange for Guillain-Barré syndrome |
| Q35149157 | Plasmapheresis in neurological disorders: Experience from a tertiary care hospital in South India. |
| Q47096767 | Plasmapheresis: A Retrospective Audit of Procedures from a Tertiary Care Center in Southern India |
| Q40665273 | Polyclonal intravenous immunoglobulin for the prophylaxis and treatment of infection in critically ill adults |
| Q72301755 | Polyradiculoneuritis as an initial manifestation of bronchial carcinoma |
| Q99565499 | Post-infectious neurological disorders |
| Q37356535 | Postinfectious Guillain-Barre syndrome in a patient with methimazole-induced agranulocytosis |
| Q91792809 | Postoperative Guillain-Barré Syndrome, a Neurologic Complication that Must Not Be Overlooked: A Literature Review |
| Q37109992 | Prediction of Functional Outcome in Axonal Guillain-Barre Syndrome |
| Q48213941 | Primary Cytomegalovirus Infection Causing Guillain-Barré Syndrome in a Living Renal Allograft Recipient. |
| Q41579230 | Prognostic factors and complication rates for double-filtration plasmapheresis in patients with Guillain-Barré syndrome |
| Q33332176 | Prominent plasmacytosis following intravenous immunoglobulin correlates with clinical improvement in Guillain-Barré syndrome |
| Q81526946 | Prospective study of children with Guillain-Barre syndrome |
| Q73126318 | Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group |
| Q26864907 | Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies |
| Q34632155 | Recent insights into the role of autoimmunity in idiopathic dilated cardiomyopathy. |
| Q41663935 | Receptors for gammaglobulin in the central and peripheral nervous system |
| Q41621447 | Rehabilitation of Guillain-Barré syndrome |
| Q64056891 | Rescue treatment in patients with poorly responsive Guillain-Barre syndrome |
| Q33735891 | Residual health status after Guillain-Barre syndrome |
| Q36262704 | Respiratory dysfunction in Guillain-Barré Syndrome |
| Q33868085 | Role of anti-GQ1B antibody in differential diagnosis of acute ophthalmoparesis |
| Q27027324 | Role of cytokines and Toll-like receptors in the immunopathogenesis of Guillain-Barré syndrome |
| Q77905779 | Schmidt-Lanterman's incisures--the principal target of autoimmune attack in demyelinating Guillain-Barré syndrome? |
| Q57259841 | Selective Digestive Tract Decontamination Decreases Time on Ventilator in Guillain–Barré Syndrome |
| Q34658942 | Selective immune adsorption treatment of severe Guillain Barré syndrome in the intensive care unit |
| Q28379144 | Serum antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in Miller Fisher syndrome |
| Q26995291 | Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration |
| Q34604677 | Sialosyl-galactose: a common denominator of Guillain-Barré and related disorders? |
| Q44322140 | Silencing of miR155 promotes the production of inflammatory mediators in Guillain-Barré syndrome in vitro |
| Q48666482 | Single dose immunoglobulin therapy for childhood Guillain-Barré syndrome |
| Q41991434 | Small volume plasma exchange for Guillain-Barré syndrome in resource poor settings: a safety and feasibility study |
| Q57928128 | Small volume plasma exchange for Guillain-Barré syndrome in resource-limited settings: a phase II safety and feasibility study |
| Q36602812 | Socio-economic aspects of neuroimmunological diseases |
| Q73595552 | Spectral analysis of heart rate and blood pressure in Guillain-Barré patients with respiratory failure |
| Q24676037 | Systematic reviews of treatment for inflammatory demyelinating neuropathy |
| Q50617920 | The Guillain-Barrè syndrome (GBS). Implementation of a register of the disease on a nationwide basis. Italian GBS Study Group. |
| Q41663315 | The Guillain-Barré syndrome: plasma exchange or immunoglobulins intravenously |
| Q40906180 | The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders |
| Q36219298 | The landry-guillain-barré strohl syndrome 1859 to 1992 a historical perspective |
| Q37706192 | The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases. |
| Q33231470 | The numbers needed to treat for neurological disorders |
| Q37237413 | The role of IVIg in autoimmune neuropathies: the latest evidence |
| Q37812002 | The role of cytokines in Guillain–Barré syndrome |
| Q35057210 | The role of intravenous immunoglobulin in the treatment of multiple sclerosis |
| Q30986945 | The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data |
| Q39134222 | Therapeutic Plasma Exchange in Patients with Neurologic Disorders: Review of 63 Cases |
| Q37106750 | Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study. |
| Q36602787 | Therapy of immune neuropathies with intravenous immunoglobulins |
| Q39476626 | Tracheostomy or Not: Prediction of Prolonged Mechanical Ventilation in Guillain-Barré Syndrome |
| Q73885779 | Treating nerves: from anecdote to systematic review |
| Q34318837 | Treatment approaches for Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy |
| Q35152989 | Treatment guidelines for Guillain-Barré Syndrome |
| Q73040167 | Treatment of Bickerstaff's brainstem encephalitis with immune globulin |
| Q36905982 | Treatment of acute pandysautonomia with intravenous immunoglobulin |
| Q36100132 | Treatment of dys-immune neuropathies. |
| Q33808870 | Treatment of the adult Guillain-Barré syndrome: indications for plasma exchange. |
| Q84618425 | Unraveling Guillain-Barrésyndrome |
| Q41808656 | Update: Intravenous immune globulin in children |
| Q102319264 | Urgent therapeutic plasma exchange |
| Q79771625 | Variability of the inhibition by total immunoglobulin of in vitro autoantibody-mediated erythrophagocytosis by mouse macrophages |
| Q36902672 | Year in review 2011: Critical Care--Neurocritical care. |
| Q80953233 | [Immunomodulatory effects of intravenous immunoglobulins] |
| Q83154740 | [Indications for intravenous immunoglobulins] |
| Q81581376 | [Intravenous immunoglobulins in chronic idiopathic myositis] |
| Q81317771 | [Intravenous immunoglobulins: therapeutic indications] |
| Q79703344 | [Plasma exchange as a therapeutic option in neurological disorders] |
| Q83060781 | [Severe Guillain-Barré syndrome and pregnancy: two cases with rapid improvement post-partum] |
| Q83179107 | [The significance of intravenous immunoglobulin in treatment of immune-mediated polyneuropathies] |
| Q73507540 | [Therapeutic indications of intravenous immunoglobulins] |
| Q74103234 | [Therapeutic plasma exchange 1996] |
| Q80257893 | [Use of i.v. immunoglobulins in neurology. Evidence-based consensus] |
| Q72185881 | [Use of immunoglobulins G in the treatment of nervous system diseases] |
Search more.